Cargando…
Objective response rate of placebo in randomized controlled trials of anticancer medicines
BACKGROUND: Spontaneous regression of advanced solid tumors is infrequent but may occur. Quantifying response rates from placebo in cancer drug trials may provide important information for physicians, patients, and regulators. We aimed to provide a pooled placebo response rate from drug trials in ad...
Autores principales: | Sachdev, Arushi, Sharpe, Isobel, Bowman, Meghan, Booth, Christopher M., Gyawali, Bishal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700265/ https://www.ncbi.nlm.nih.gov/pubmed/36444211 http://dx.doi.org/10.1016/j.eclinm.2022.101753 |
Ejemplares similares
-
Letter to Editor-response: placebo response rates
por: Gyawali, Bishal
Publicado: (2023) -
Text Messaging in Cancer-Supportive Care: A Systematic Review
por: Wijeratne, Don Thiwanka, et al.
Publicado: (2021) -
Endpoints used in phase III randomized controlled trials of treatment options for COVID-19
por: Desai, Aakash, et al.
Publicado: (2020) -
Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity
por: Sengar, Manju, et al.
Publicado: (2023) -
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
por: Sharma, Shubham, et al.
Publicado: (2021)